Medtronic wins FDA nod for InterStim sacral neuromod programmer

Medtronic (NYSE:MDT) said today that the FDA approved its InterStim smart programmer, designed to work with the company’s InterStim sacral neurmodulation system intended for tor treating overactive bladder, chronic fecal incontinence and non-obstructive urinary retention. The newly cleared smart programmer is run on a Samsung Electronics (LON:BC94) mobile device and allows clinicians to personalize patient care and manage therapy from a single access point, the Fridley, Minn.-based medical giant said. “The incorporation of consumer technology in medical device solutions, such as the InterStim system, is not only helping patients integrate these solutions into their daily lives, it’s also empowering clinicians to evolve and digitally transform their practice. Medtronic continues to lead the market in these types of healthcare innovations, and we are proud to partner with them to bring these important solutions to patients and clinicians,” Samsung Electronics America chief medical officer Dr. David Rhew said in a press release. Medtronic’s InterStim programmer uses an app-based platform that allows for implant and long-term therapy management, allowing physicians to check magnetic resonance imaging eligibility and access to detailed views of a patient’s therapy experience, the company said. “Medtronic pioneered sacral neuromodulation two decades ago and we continue to innovate to improve the patient and physician experience and make ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Medtronic samsung Source Type: news